Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus PEDIAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus PEDIAPRED.
FLOVENT DISKUS 50 vs PEDIAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
Prednisolone is a glucocorticoid receptor agonist that binds to the intracellular glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune responses by reducing lymphocyte proliferation and activity.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
Oral: 5-60 mg/day as a single dose or divided doses; adjust based on condition and response.
None Documented
None Documented
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
2.5–3.5 hours (terminal) in children; clinical context: requires multiple daily doses for sustained effect.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Renal: ~80% as metabolites (mainly glucuronides and sulfates) and <5% unchanged; fecal: ~15%.
Category C
Category C
Corticosteroid
Corticosteroid